Sandoz

News

Roche's blockbuster breast cancer drug Herceptin

Sandoz strikes deal with EirGenix for Herceptin biosimilar

Sandoz has struck a deal with Taiwan-based EirGenix to market a late-stage biosimilar of Roche’s breast cancer blockbuster Herceptin.

News

Sandoz to commercialise opioid induced constipation tablet i...

As it continues to look into drugs that can help opioid-dependant patients, Sandoz has signed an agreement with Shionogi to commercialise Rizmoic (naldemedine) in the key European markets

News

CEO of Novartis' generics unit quits, sparking sale speculat...

Richard Francis is stepping down as CEO of Novartis’ generics and biosimilars division Sandoz at the end of March, sparking further speculation about the unit’s future.

News

Sandoz announces results of digital innovation 'HACk'

A digital therapeutic for irritable bowel syndrome, a developing world disease diagnosis tool, and a mobile maternity clinic in Uganda, were the three winners of Sandoz’s competition to imp

News

Sandoz selects finalists in digital tech healthcare access c...

Sandoz has selected three finalists in a competition to use digital technology to increase access to medicines in poorer countries.

News

Sandoz joins medical cannabis drive with Tilray deal

Novartis’ Sandoz subsidiary has taken its first steps into the emerging market for medical cannabis products, signing a global supply deal with Canadian producer Tilray.

Sandoz strikes deal with EirGenix for Herceptin biosimilar

Sandoz to commercialise opioid induced constipation tablet i...

CEO of Novartis' generics unit quits, sparking sale speculat...

Sandoz announces results of digital innovation 'HACk'

Sandoz selects finalists in digital tech healthcare access c...

Sandoz joins medical cannabis drive with Tilray deal

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Sandoz

Editor's Picks